Welcome to our dedicated page for Alps Group SEC filings (Ticker: ALPS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alps Group Inc filings document the company's foreign private issuer current-report disclosures following its completed SPAC business combination and public-company transition. Form 6-K reports furnish material-event updates, press releases, governance changes, board appointments, committee service, executive leadership appointments, employment agreement terms, capital-structure matters, and security-structure disclosures.
The filing record also covers company-specific biotechnology disclosures, including peer-reviewed case reports involving autologous Natural Killer cell infusions produced with an in-house culture protocol and CELESOME(+) exosome-related development activities. These documents frame Alps Group's formal disclosures around clinical-program communications, corporate governance, material agreements, and operating and financial reporting categories.
Alps Group Inc executive Low Wei Sim, the Chief Operating Officer, has filed an initial ownership report showing a direct holding of 821,083 Ordinary Shares. This filing is a Form 3, which records the officer’s existing stake and does not reflect a new buy or sell transaction.
Alps Group Inc director and Chief Executive Officer Tham Seng Kong filed an initial ownership report showing a substantial direct stake in the company. The filing reports beneficial ownership of 77,144,380 Ordinary Shares, confirming his status as a major, more than ten percent, shareholder.
Alps Group Inc filed a Form 6-K highlighting a peer-reviewed case series of its autologous Natural Killer (NK) cell therapy using an in-house culture protocol. The study in SAGE Open Medical Case Reports followed nine patients treated at ALPS Medical Centre between 2023 and 2024.
Patients were monitored for blood counts, liver function, hypersensitivity, inflammatory markers and tumor markers to evaluate safety and potential toxic or dose-dependent adverse reactions. The case series provided evidence of clinical tolerability of autologous NK cells produced with the company’s proprietary protocol and complied with Malaysian Good Clinical Practice and the Declaration of Helsinki.
The company also emphasized a patent-pending, antibody-free culture method that aims to enable cost-effective, large-scale production of highly pure NK cells using basic media and autologous plasma. These preliminary data, together with preclinical GLP findings, are intended to support future clinical investigations in a broader patient population.
Alps Group Inc reports pro forma results and structure following its business combination with Globalink Investment Inc and Alps Life Sciences Inc. The all-share deal values the transaction at $1.6 billion, with former Alps Holdco shareholders receiving 160,000,000 PubCo ordinary shares and owning about 96.1% of the combined company.
The filing includes IFRS-based pro forma financials showing a net loss of $3.6 million for the six months ended September 30, 2025, or $0.02 per share, and a net loss of $66.2 million for the year ended March 31, 2025, or $0.40 per share, largely driven by a nonrecurring $59.46 million IFRS 2 listing expense and other transaction costs.
The structure also reflects $3,107,731 of PIPE financing for 310,788 shares, redemptions of 337,477 Globalink shares for about $3.39 million, and a finder’s fee and advisory equity that, together with PIPE investors and SPAC holders, leave legacy Globalink securityholders with a small minority interest.
Alps Group Inc reports a potential expansion of its exosome-related pipeline beyond its CELESOME(+) programme, based on a newly published retrospective clinical case series of nebulized human umbilical cord mesenchymal stem cell-derived exosomes in patients with asthma and chronic obstructive pulmonary disease.
The peer-reviewed report describes investigational, once-weekly inhaled dosing over five weeks using a medical-grade nebulizer, with observations that included improved pulmonary function, stable inflammatory markers, and no significant adverse effects. Management emphasizes these findings are preliminary and that larger, controlled studies are required, with no assurances on eventual clinical success or regulatory approval.
Alps Group Inc is registering up to 6,035,000 ordinary shares issuable upon exercise of outstanding warrants and up to 5,725,546 ordinary shares for resale by existing shareholders. The resale shares represent about 3.44% of the 166,400,326 ordinary shares outstanding as of this prospectus and include founder, PIPE, director and Business Combination consideration shares, some acquired at prices far below the current market price.
The company operates an integrated biotech, medical and wellness platform based in Malaysia. Its pipeline is entirely preclinical, so current revenue comes from aesthetic, healthcare and wellness services used to fund research in areas such as precision and preventive medicine. Warrants are exercisable at $11.50 per share, while the ordinary shares recently closed at $1.00, making exercises unlikely at present.
Key risks include the need for substantial additional funding, a material weakness in internal control over financial reporting, early‑stage clinical and regulatory uncertainty, dependence on third‑party manufacturing, potential selling pressure from registered resale shares, and the challenges of operating as an emerging growth, foreign private issuer based largely in Malaysia.
Alps Group Inc reported that its board appointed Cheing Lye-Ping (Penny) as Chief Financial Officer, effective January 5, 2026. She will lead financial strategy, budgeting, planning and analysis, audit, tax compliance, risk management, accounting, and treasury for the company and its subsidiaries.
Ms. Cheing brings over 30 years of finance and accounting experience, including prior roles as CFO and CEO in Malaysian property and investment businesses, as well as earlier work at Arthur Andersen across multiple industries. Under a one-year executive employment agreement, she will receive an annual base salary of $59,000, with standard benefits and negotiated severance if terminated without cause or for Just Cause as defined in the agreement. The company states there are no family relationships or special arrangements connected to her appointment.